The great hype around appetite suppressants is again causing supply problems for the Danish insulin specialist Novo Nordisk. According to a note from the company to the US drug regulator FDA on Tuesday evening, Saxenda now also suffers from bottlenecks after the blockbuster Wegovy. This is a somewhat older means of supporting weight loss.
Accordingly, Saxenda should be available in limited quantities until the end of the year. Also moreover, there may still be difficulties in meeting demand.
Supports the treatment of obesity
“We are currently seeing demand for Saxenda increase significantly,” said a company spokeswoman. The pharmaceutical industry is experiencing an explosion of weight loss drugs. The new drugs such as Wegovy are intended to accompany a diet in morbid obesity with a body mass index of 30 or more (obesity).
Weight-loss madness weighs heavily on the pharmaceutical industry
However, more and more people who do not fall under this definition are also reaching for the means. The beauty and diet wave is booming in the US in particular: medicines there are often sold “off-label” – ie outside their officially approved areas of application – even to people with less or no overweight. As a result, affected manufacturers such as Novo Nordisk, Eli Lilly and Roche experienced delivery problems on several occasions.
Many people are now also switching to older products such as Saxenda. The drug has been on the market for almost ten years. Although it contains the same active ingredient (semaglutide) as Wegovy, it is considered less effective than the younger drug.
Source: Krone
I am Wallace Jones, an experienced journalist. I specialize in writing for the world section of Today Times Live. With over a decade of experience, I have developed an eye for detail when it comes to reporting on local and global stories. My passion lies in uncovering the truth through my investigative skills and creating thought-provoking content that resonates with readers worldwide.
